Thomas Jefferson University

Hie-Won Hann

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentMedicine
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-8900
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Juon HS, Yang D, Fang CX, Hann HW, Bae H, Chang M, Klassen AC. Perceived HBV-Related Stigma Is Associated With Lower Antiviral Medication Adherence in Patients With Chronic Hepatitis B. J Viral Hepat. 2025 Mar; 32(3):e70010. PMID: 39953814.
      Citations:    
    2. Lee G, Juon H, Kim E, Smith KC, Hann HW, Chang M, Klassen AC. HBV Transmission Knowledge Among Korean-American Chronic Hepatitis B Patients in the United States. J Community Health. 2025 Apr; 50(2):306-316. PMID: 39487356.
      Citations:    
    3. Katcher JG, Klassen AC, Hann HW, Chang M, Juon HS. Racial discrimination, knowledge, and health outcomes: The mediating role of hepatitis B-related stigma among patients with chronic hepatitis B. J Viral Hepat. 2024 05; 31(5):248-254. PMID: 38409935.
      Citations:    
    4. Varghese N, Majeed A, Nyalakonda S, Boortalary T, Halegoua-DeMarzio D, Hann HW. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cancers (Basel). 2024 Feb 14; 16(4). PMID: 38398168.
      Citations:    
    5. Yuen MF, Fung S, Ma X, Nguyen TT, Hassanein T, Hann HW, Elkhashab M, Nahass RG, Park JS, Jacobson IM, Ayoub WS, Han SH, Gane EJ, Zomorodi K, Yan R, Ma J, Knox SJ, Stamm LM, Bonacini M, Weilert F, Ramji A, Bennett M, Ravendhran N, Chan S, Dieterich DT, Kwo PY, Schiff ER, Bae HS, Lalezari J, Agarwal K, Sulkowski MS. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses. JHEP Rep. 2024 Apr; 6(4):100999. PMID: 38510983.
      Citations:    
    6. Lin SY, Xia W, Kim AK, Chen D, Schleyer S, Choi L, Wang Z, Hamilton JP, Luu H, Hann HW, Chang TT, Hu CT, Woodard A, Gade TP, Su YH. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma. Sci Rep. 2023 12 07; 13(1):21585. PMID: 38062093.
      Citations:    
    7. Fung SK, Pan CQ, Wong GL, Seto WK, Ahn SH, Chen CY, Hann HL, Jablkowski MS, Kim YJ, Yurdaydin C, Peng CY, Nguyen T, Yatsuhashi H, Flaherty JF, Yee LJ, Abramov F, Wang H, Abdurakhmanov D, Lim YS, Buti M. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96?weeks. Aliment Pharmacol Ther. 2024 01; 59(2):217-229. PMID: 37905449.
      Citations:    
    8. Lin D, Luo R, Ye Z, Wei Q, Bae H, Juon HS, Hann HW, Posey J, Wang C. Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA. Clin Res Hepatol Gastroenterol. 2023 08; 47(7):102161. PMID: 37307947.
      Citations:    
    9. Lin SY, Halegoua-DeMarzio D, Block P, Kao YL, Civan J, Shieh FS, Song W, Hann HW, Su YH. Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study. Diagnostics (Basel). 2023 Apr 25; 13(9). PMID: 37174929.
      Citations:    
    10. Noverati N, Nguyen A, Chalikonda D, Halegoua-DeMarzio D, Hann HW. The Role of Host in the Spectrum of Outcomes in Family Clusters of Hepatitis Infection: From Asymptomatic to Hepatocellular Carcinoma. Case Rep Gastroenterol. 2023 Jan-Dec; 17(1):104-110. PMID: 36818365.
      Citations:    
    11. Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Safety and efficacy of vebicorvir administered with entecavir in treatment-na?ve patients with chronic hepatitis B virus infection. J Hepatol. 2022 11; 77(5):1265-1275. PMID: 35697332.
      Citations:    
    12. Pan CQ, Afdhal NH, Ankoma-Sey V, Bae H, Curry MP, Dieterich D, Frazier L, Frick A, Hann HW, Kim WR, Kwo P, Milligan S, Tong MJ, Reddy KR. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatol Commun. 2022 08; 6(8):1881-1894. PMID: 35445803.
      Citations:    
    13. Yuen MF, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Sulkowski MS. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. J Hepatol. 2022 09; 77(3):642-652. PMID: 35460726.
      Citations:    
    14. Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-DeMarzio D, Hann HW. Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level. Viruses. 2022 04 08; 14(4). PMID: 35458505.
      Citations:    
    15. Noverati N, Bashir-Hamidu R, Halegoua-DeMarzio D, Hann HW. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress. Int J Mol Sci. 2022 Apr 01; 23(7). PMID: 35409275.
      Citations:    
    16. Kim AK, Hamilton JP, Lin SY, Chang TT, Hann HW, Hu CT, Lou Y, Lin YJ, Gade TP, Park G, Luu H, Lee TJ, Wang J, Chen D, Goggins MG, Jain S, Song W, Su YH. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. 2022 06; 126(10):1432-1438. PMID: 35046521.
      Citations:    
    17. Lin SY, Su YP, Trauger ER, Song BP, Thompson EGC, Hoffman MC, Chang TT, Lin YJ, Kao YL, Cui Y, Hann HW, Park G, Shieh FS, Song W, Su YH. Detection of Hepatitis B Virus-Host Junction Sequences in Urine of Infected Patients. Hepatol Commun. 2021 10; 5(10):1649-1659. PMID: 34558837.
      Citations:    
    18. Bashir Hamidu R, Chalikonda DM, Hann HW. Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series. Vaccines (Basel). 2021 Jul 30; 9(8). PMID: 34451963.
      Citations:    
    19. Block PD, Shinn B, Kim JH, Hann HW. Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes. Hepat Oncol. 2020 Dec 29; 8(1):HEP35. PMID: 33680431.
      Citations:    
    20. Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol. 2020 02; 18(2):457-467.e21. PMID: 31306800.
      Citations:    
    21. Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol. 2019 Jan 27; 11(1):65-73. PMID: 30705719.
      Citations:    
    22. Bian Z, Hann HW, Ye Z, Yin C, Wang Y, Fang W, Wan S, Wang C, Tao K. Ferritin level prospectively predicts hepatocarcinogenesis in patients with chronic hepatitis B virus infection. Oncol Lett. 2018 Sep; 16(3):3499-3508. PMID: 30127954.
      Citations:    
    23. Yoo J, Hann HW, Coben R, Conn M, DiMarino AJ. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases. 2018 Apr 20; 6(2). PMID: 29677098.
      Citations:    
    24. Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther. 2018 Apr; 47(8):1181-1200. PMID: 29479728.
      Citations:    
    25. Hann HW, Jain S, Park G, Steffen JD, Song W, Su YH. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. Hepatoma Res. 2017; 3:105-111. PMID: 28795155.
      Citations:    
    26. Wan S, Hann HW, Ye Z, Hann RS, Lai Y, Wang C, Li L, Myers RE, Li B, Xing J, Yang H. Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients. Carcinogenesis. 2017 04 01; 38(4):439-446. PMID: 28334112.
      Citations:    
    27. Dargan A, Wong SY, Coben R, Conn M, Dimarino AJ, Hann HW. Persistent risk for hepatocellular carcinoma after more than a decade of successful hepatitis B virus suppression. Minerva Gastroenterol Dietol. 2017 Mar; 63(1):74-76. PMID: 28054479.
      Citations:    
    28. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Kim K, Kitrinos KM, Subramanian GM, McHutchison JG, Yee LJ, Elkhashab M, Berg T, Sporea I, Yurdaydin C, Husa P, Jablkowski MS, Gane E. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2017 01; 66(1):11-18. PMID: 27545497.
      Citations:    
    29. Ahn J, Lim JK, Lee HM, Lok AS, Nguyen M, Pan CQ, Mannalithara A, Te H, Reddy KR, Trinh H, Chu D, Tran T, Lau D, Leduc TS, Min A, Trong Le L, Bae H, Van Tran S, Do S, Hann HW, Wong C, Han S, Pillai A, Park JS, Tong M, Scaglione S, Woog J, Kim WR. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. Am J Gastroenterol. 2016 09; 111(9):1297-304. PMID: 27325221.
      Citations:    
    30. Li L, Hann HW, Wan S, Hann RS, Wang C, Lai Y, Ye X, Evans A, Myers RE, Ye Z, Li B, Xing J, Yang H. Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. Sci Rep. 2016 Apr 11; 6:23992. PMID: 27063412.
      Citations:    
    31. Wang M, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z, Rinaudo JA, Srivastava S, Evans A, Hann HW, Lai Y, Yang H, Block TM, Mehta A. The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. Cancer Prev Res (Phila). 2016 Feb; 9(2):172-9. PMID: 26712941.
      Citations:    
    32. Civan J, Hann HW. Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough? Expert Opin Drug Saf. 2015 Jun; 14(6):865-75. PMID: 25826452.
      Citations:    
    33. Wang C, Hann HW, Hann RS, Wan S, Myers RE, Ye Z, Xing J, Yang H. Circulating mitochondrial DNA content associated with the risk of liver cirrhosis: a nested case-control study. Dig Dis Sci. 2015 Jun; 60(6):1707-15. PMID: 25588520.
      Citations:    
    34. Hann HW, Wan S, Lai Y, Hann RS, Myers RE, Patel F, Zhang K, Ye Z, Wang C, Yang H. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2015 Jan; 30(1):131-138. PMID: 24995497.
      Citations:    
    35. Halegoua-De Marzio D, Hann HW. Prevention of hepatocellular carcinoma and its recurrence with anti-hepatitis B viral therapy. Minerva Gastroenterol Dietol. 2014 Sep; 60(3):191-200. PMID: 25000955.
      Citations:    
    36. Hann HW. Advances in the management of hepatitis B virus infection. Gastroenterol Hepatol (N Y). 2014 Jun; 10(6):384-6. PMID: 25013391.
      Citations:    
    37. Hann HW, Coben R, Brown D, Needleman L, Rosato E, Min A, Hann RS, Park KB, Dunn S, DiMarino AJ. A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med. 2014 Apr; 3(2):390-6. PMID: 24519810.
      Citations:    
    38. Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol. 2014 Jan 14; 20(2):401-13. PMID: 24574709.
      Citations:    
    39. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014 Apr; 146(4):980-8. PMID: 24368224.
      Citations:    
    40. Lee H, Kiang P, Chea P, Peou S, Tang SS, Yang J, Fawcett J, Hann HW. HBV-related health behaviors in a socio-cultural context: perspectives from Khmers and Koreans. Appl Nurs Res. 2014 May; 27(2):127-32. PMID: 24355416.
      Citations:    
    41. Petruzzi NJ, Frangos AJ, Fenkel JM, Herrine SK, Hann HW, Rossi S, Rosato EL, Eschelman DJ, Gonsalves CF, Brown DB. Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma. J Vasc Interv Radiol. 2013 Feb; 24(2):266-73. PMID: 23261143.
      Citations:    
    42. Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B, Yang H. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One. 2012; 7(10):e47687. PMID: 23112834.
      Citations:    
    43. Lee H, Fawcett J, Yang JH, Hann HW. Correlates of hepatitis B virus health-related behaviors of Korean Americans: a situation-specific nursing theory. J Nurs Scholarsh. 2012 Dec; 44(4):315-22. PMID: 23057710.
      Citations:    
    44. Wan S, Hann HW, Myers RE, Fu X, Hann RS, Kim SH, Tang H, Xing J, Yang H. Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: a nested case-control analysis. Liver Int. 2012 Sep; 32(8):1233-41. PMID: 22471856.
      Citations:    
    45. Fu X, Wan S, Hann HW, Myers RE, Hann RS, Au J, Chen B, Xing J, Yang H. Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. Eur J Cancer. 2012 May; 48(7):1014-22. PMID: 22444598.
      Citations:    
    46. Hann HW, Fu X, Myers RE, Hann RS, Wan S, Kim SH, Au N, Xing J, Yang H. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection--results from a clinic-based longitudinal cohort. Eur J Cancer. 2012 Oct; 48(15):2319-27. PMID: 22436980.
      Citations:    
    47. Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci. 2011 Nov; 56(11):3143-62. PMID: 21935699.
      Citations:    
    48. Lee H, Hann HW, Yang JH, Fawcett J. Recognition and management of HBV infection in a social context. J Cancer Educ. 2011 Sep; 26(3):516-21. PMID: 21347651.
      Citations:    
    49. Hann HW, Bergin D, Coben R, DiMarino AJ. Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated. Int J Cancer. 2011 Feb 01; 128(3):739-42. PMID: 20473872.
      Citations:    
    50. Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int. 2011 Jun; 5(2):654-63. PMID: 21484148.
      Citations:    
    51. Hann HW. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother. 2010 Sep; 11(13):2243-9. PMID: 20698726.
      Citations:    
    52. Hann HW, Dunn SR, Ahn M, Park SY. Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009). J Med Virol. 2010 Sep; 82(9):1489-93. PMID: 20648601.
      Citations:    
    53. Hann HW, Wang M, Hafner J, Long RE, Kim SH, Ahn M, Park S, Comunale MA, Block TM, Mehta A. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomark. 2010; 7(6):269-73. PMID: 21694465.
      Citations:    
    54. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009 Jan; 49(1):72-9. PMID: 19065670.
      Citations:    
    55. Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int. 2008 Dec; 2(4):440-56. PMID: 19669319.
      Citations:    
    56. Lim SG, Leung N, Hann HW, Lau GK, Trepo C, Mommeja-Marin H, Moxham C, Sorbel J, Snow A, Blum MR, Rousseau F, Marcellin P. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2008 Jun; 27(12):1282-92. PMID: 18363895.
      Citations:    
    57. Hann HW. Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2008 Mar; 54(1):19-30. PMID: 18299665.
      Citations:    
    58. Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int. 2008 Jun; 2(2):244-9. PMID: 19669311.
      Citations:    
    59. Hann HW, Han SH, Block TM, Harris M, Maa JF, Fisher RT, Atillasoy E. Symptomatology and health attitudes of chronic hepatitis B patients in the USA. J Viral Hepat. 2008 Jan; 15(1):42-51. PMID: 18088244.
      Citations:    
    60. Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol. 2007 Aug 14; 13(30):4085-90. PMID: 17696226.
      Citations:    
    61. Choi D, Mitchell DG, Verma SK, Bergin D, Navarro VJ, Malliah AB, McGowan C, Hann HW, Herrine SK. Hepatocellular carcinoma with indeterminate or false-negative findings at initial MR imaging: effect on eligibility for curative treatment initial observations. Radiology. 2007 Sep; 244(3):776-83. PMID: 17690322.
      Citations:    
    62. Chae HB, Hann HW. Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection. Ther Clin Risk Manag. 2007 Aug; 3(4):605-12. PMID: 18472982.
      Citations:    
    63. Hann HW, Hann RS, Maddrey WC. Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol. 2007 Apr; 102(4):767-72. PMID: 17397407.
      Citations:    
    64. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, Evans AA, Hann HW, Block TM, Mehta AS. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006 Feb; 5(2):308-15. PMID: 16457596.
      Citations:    
    65. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005 Aug; 129(2):528-36. PMID: 16083710.
      Citations:    
    66. Hann HW, Jonsson Funk ML, Rosenberg DM, Davis R. Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. J Gastroenterol Hepatol. 2005 Mar; 20(3):433-40. PMID: 15740489.
      Citations:    
    67. Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K, Clayton MM, Ardlie K, Pellini MJ, Feitelson MA. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res. 2004 Oct 15; 64(20):7329-35. PMID: 15492253.
      Citations:    
    68. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004 Jan; 126(1):81-90. PMID: 14699490.
      Citations:    
    69. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner SD, Brown N, Griffiths D. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003 Jan; 9(1):49-56. PMID: 12514773.
      Citations:    
    70. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan; 124(1):105-17. PMID: 12512035.
      Citations:    
    71. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002 Sep; 123(3):719-27. PMID: 12198698.
      Citations:    
    72. Jeong YY, Mitchell DG, Hann HW, Malin AK, Kang HK, Holland GA, Capizzi RL. Hepatocellular carcinoma after systemic chemotherapy: gadolinium-enhanced mr measurement of necrosis by volume histogram. J Comput Assist Tomogr. 2001 Jul-Aug; 25(4):624-8. PMID: 11473196.
      Citations:    
    73. Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Riker-Hopkins M, Brown N. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl. 2001 Jun; 7(6):504-10. PMID: 11443577.
      Citations:    
    74. Kim MJ, Mitchell DG, Ito K, Hann HW, Park YN, Kim PN. Hepatic iron deposition on MR imaging in patients with chronic liver disease: correlation with serial serum ferritin concentration. Abdom Imaging. 2001 Mar-Apr; 26(2):149-56. PMID: 11178691.
      Citations:    
    75. Brodeur GM, Look AT, Shimada H, Hamilton VM, Maris JM, Hann HW, Leclerc JM, Bernstein M, Brisson LC, Brossard J, Lemieux B, Tuchman M, Woods WG. Biological aspects of neuroblastomas identified by mass screening in Quebec. Med Pediatr Oncol. 2001 Jan; 36(1):157-9. PMID: 11464873.
      Citations:    
    76. Kunkel EJ, Kim JS, Hann HW, Oyesanmi O, Menefee LA, Field HL, Lartey PL, Myers RE. Depression in Korean immigrants with hepatitis B and related liver diseases. Psychosomatics. 2000 Nov-Dec; 41(6):472-80. PMID: 11110110.
      Citations:    
    77. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999 Oct 21; 341(17):1256-63. PMID: 10528035.
      Citations:    
    78. Ito K, Mitchell DG, Hann HW, Kim Y, Fujita T, Okazaki H, Honjo K, Matsunaga N. Viral-induced cirrhosis: grading of severity using MR imaging. AJR Am J Roentgenol. 1999 Sep; 173(3):591-6. PMID: 10470885.
      Citations:    
    79. Ito K, Mitchell DG, Gabata T, Hann HW, Kim PN, Fujita T, Awaya H, Honjo K, Matsunaga N. Hepatocellular carcinoma: association with increased iron deposition in the cirrhotic liver at MR imaging. Radiology. 1999 Jul; 212(1):235-40. PMID: 10405747.
      Citations:    
    80. Ito K, Mitchell DG, Hann HW, Outwater EK, Kim Y, Fujita T, Okazaki H, Honjo K, Matsunaga N. Progressive viral-induced cirrhosis: serial MR imaging findings and clinical correlation. Radiology. 1998 Jun; 207(3):729-35. PMID: 9609897.
      Citations:    
    81. Martin P, Hann HW, Westerberg S, Mu?oz SJ, Rubin R, Maddrey WC. Interferon-alpha2b therapy is efficacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trial. Dig Dis Sci. 1998 Apr; 43(4):875-9. PMID: 9580255.
      Citations:    
    82. Hann HW. Prevention and Treatment of Primary Hepatocellular Carcinoma in Asian Americans. Asian Am Pac Isl J Health. 1998; 6(2):292-301. PMID: 11567453.
      Citations:    
    83. Ito K, Mitchell DG, Hann HW, Outwater EK, Kim Y. Compensated cirrhosis due to viral hepatitis: using MR imaging to predict clinical progression. AJR Am J Roentgenol. 1997 Sep; 169(3):801-5. PMID: 9275900.
      Citations:    
    84. Sadek AG, Mitchell DG, Siegelman ES, Outwater EK, Matteucc? T, Hann HW. Early hepatocellular carcinoma that develops within macroregenerative nodules: growth rate depicted at serial MR imaging. Radiology. 1995 Jun; 195(3):753-6. PMID: 7754006.
      Citations:    
    85. Jacobs JM, Martin P, Munoz SJ, Westerberg S, Hann HW, Moritz MJ, Rubin R, Yang S, Radomski J, Jarrell BE. Liver transplantation for chronic hepatitis B in Asian males. Transplant Proc. 1993 Apr; 25(2):1904-6. PMID: 8470221.
      Citations:    
    86. Mitchell DG, Lovett KE, Hann HW, Ehrlich S, Palazzo J, Rubin R. Cirrhosis: multiobserver analysis of hepatic MR imaging findings in a heterogeneous population. J Magn Reson Imaging. 1993 Mar-Apr; 3(2):313-21. PMID: 8448392.
      Citations:    
    87. Kim IY, Mitchell DG, Vinitski S, Consigny PM, Hann HW, Rifkin MD, Rubin R. MR imaging of hepatic iron overload in rat. J Magn Reson Imaging. 1993 Jan-Feb; 3(1):67-70. PMID: 8428103.
      Citations:    
    88. Palazzo JP, Lundquist K, Mitchell D, Mittal KR, Hann HW, Munoz S, Moritz MJ, Jacobs JM, Martin P. Rapid development of lymphoma following liver transplantation in a recipient with hepatitis B and primary hemochromatosis. Am J Gastroenterol. 1993 Jan; 88(1):102-4. PMID: 8380533.
      Citations:    
    89. Hann HW, Stahlhut MW, Rubin R, Maddrey WC. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer. 1992 Oct 15; 70(8):2051-6. PMID: 1327484.
      Citations:    
    90. Moody DE, Loury DN, Hammock BD, Ruebner BH, Cullen JM, Hillman JH, Hillman DW, Rao MS, London WT, Hann HW, et al. Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury. Cancer Epidemiol Biomarkers Prev. 1992 Jul-Aug; 1(5):395-403. PMID: 1339049.
      Citations:    
    91. Mitchell DG, Palazzo J, Hann HW, Park CH, Tempany C, Chako A, Rubin R. Mass-like hepatic hypertrophy: MRI findings with histologic correlation. Magn Reson Imaging. 1992; 10(4):541-7. PMID: 1501524.
      Citations:    
    92. Hann HW, Stahlhut MW, Menduke H. Iron enhances tumor growth. Observation on spontaneous mammary tumors in mice. Cancer. 1991 Dec 01; 68(11):2407-10. PMID: 1657354.
      Citations:    
    93. Simon D, London T, Hann HW, Knowles BB. Chromosome abnormalities in peripheral blood cells of hepatitis B virus chronic carriers. Cancer Res. 1991 Nov 15; 51(22):6176-9. PMID: 1657381.
      Citations:    
    94. Mitchell DG, Palazzo J, Hann HW, Rifkin MD, Burk DL, Rubin R. Hepatocellular tumors with high signal on T1-weighted MR images: chemical shift MR imaging and histologic correlation. J Comput Assist Tomogr. 1991 Sep-Oct; 15(5):762-9. PMID: 1653279.
      Citations:    
    95. Siegelman ES, Mitchell DG, Rubin R, Hann HW, Kaplan KR, Steiner RM, Rao VM, Schuster SJ, Burk DL, Rifkin MD. Parenchymal versus reticuloendothelial iron overload in the liver: distinction with MR imaging. Radiology. 1991 May; 179(2):361-6. PMID: 2014275.
      Citations:    
    96. Hann HW, Lange B, Stahlhut MW, McGlynn KA. Prognostic importance of serum transferrin and ferritin in childhood Hodgkin's disease. Cancer. 1990 Jul 15; 66(2):313-6. PMID: 2369713.
      Citations:    
    97. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology. 1990 Apr; 11(4):566-9. PMID: 2158479.
      Citations:    
    98. Hann HW, Stahlhut MW, Lee S, London WT, Hann RS. Effects of isoferritins on human granulocytes. Cancer. 1989 Jun 15; 63(12):2492-6. PMID: 2720599.
      Citations:    
    99. Hann HW, Kim CY, London WT, Blumberg BS. Increased serum ferritin in chronic liver disease: a risk factor for primary hepatocellular carcinoma. Int J Cancer. 1989 Mar 15; 43(3):376-9. PMID: 2538399.
      Citations:    
    100. Hann HW, Stahlhut MW, Evans AE. Basic and acidic isoferritins in the sera of patients with neuroblastoma. Cancer. 1988 Sep 15; 62(6):1179-82. PMID: 3409187.
      Citations:    
    101. Hann HW, Stahlhut MW, Blumberg BS. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res. 1988 Aug 01; 48(15):4168-70. PMID: 3390810.
      Citations:    
    102. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factor in neuroblastoma. Cancer. 1987 Jun 01; 59(11):1853-9. PMID: 3567848.
      Citations:    
    103. Stevens RG, Morris JS, Hann HW, Pulsipher B, Stahlhut MW. Serum selenium assay following serum ferritin assay. Am J Epidemiol. 1986 Aug; 124(2):329-31. PMID: 3728447.
      Citations:    
    104. Hann HW, Stahlhut MW, Evans AE. Source of increased ferritin in neuroblastoma: studies with concanavalin A-sepharose binding. J Natl Cancer Inst. 1986 Jun; 76(6):1031-3. PMID: 3458940.
      Citations:    
    105. McGlynn K, London WT, Hann HW, Sharrar RG. Prevention of primary hepatocellular carcinoma in Asian populations in the Delaware Valley. Prog Clin Biol Res. 1986; 216:237-46. PMID: 2425372.
      Citations:    
    106. Hann HW, Evans AE, Siegel SE, Wong KY, Sather H, Dalton A, Hammond D, Seeger RC. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res. 1985 Jun; 45(6):2843-8. PMID: 3986811.
      Citations:    
    107. Kim CY, Bae SK, Hann HW, London WT, Blumberg BS. Prevalence of HBeAg and anti-HBe in chronic active hepatitis, cirrhosis and primary hepatocellular carcinoma in Korea. Hepatology. 1985 Jan-Feb; 5(1):54-6. PMID: 2981763.
      Citations:    
    108. Hann HW, Stahlhut MW, Evans AE. Serum ferritin as a prognostic indicator in neuroblastoma: biological effects of isoferritins. Prog Clin Biol Res. 1985; 175:331-45. PMID: 3873075.
      Citations:    
    109. Hann HW, Stahlhut MW, Chung LC. Inhibitory effects of isoferritins from tumour and non-tumour tissues on E-rosette formation. Lancet. 1984 Jan 07; 1(8367):43. PMID: 6140361.
      Citations:    
    110. Lustbader ED, Hann HW, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science. 1983 Apr 22; 220(4595):423-5. PMID: 6301008.
      Citations:    
    111. Hann HW, Kim CY, London WT, Whitford P, Blumberg BS. Hepatitis B virus and primary hepatocellular carcinoma: family studies in Korea. Int J Cancer. 1982 Jul 15; 30(1):47-51. PMID: 6288579.
      Citations:    
    112. Hann HW, Evans AE, Cohen IJ, Leitmeyer JE. Biologic differences between neuroblastoma stages IV-S and IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med. 1981 Aug 20; 305(8):425-9. PMID: 7254280.
      Citations:    
    113. Hann HW, Lustbader ED, Evans AE, Toledano SR, Lillie PD, Jasko LB. Lack of influence of T-cell marker and importance of mediastinal mass on the prognosis of acute lymphocytic leukemias of childhood. J Natl Cancer Inst. 1981 Feb; 66(2):285-90. PMID: 6969813.
      Citations:    
    114. Hann HW, London WT, Evans AE, Hann RS. Leukocyte migration inhibition of leukemia-associated antigen in children with acute leukemia and their family members. Cancer. 1980 Jul 15; 46(2):293-8. PMID: 6966964.
      Citations:    
    115. Hann HW, Levy HM, Evans AE. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res. 1980 May; 40(5):1411-3. PMID: 6245792.
      Citations:    
    116. Hann HW, Festa RS, Rosenstock JG, Cifuentes E. Polycythemia vera in a child with acute lymphocytic leukemia. Cancer. 1979 May; 43(5):1862-5. PMID: 286632.
      Citations:    
    117. Raney RB, Mohanakumar T, Metzgar RS, Hann HW, Donaldson MH. Childhood lymphoblastic cancer: subgroups defined by nonhuman primate antisera to human lymphatic leukemia cell antigens. J Natl Cancer Inst. 1977 May; 58(5):1217-20. PMID: 300808.
      Citations:    
    118. Hann HW, London WT, Evans AE. Lymphoblasts with T-cell markers in five girls with acute lymphocytic leukemia. Cancer. 1977 May; 39(5):2001-3. PMID: 300649.
      Citations:    
    119. Hann HW, London WT, Evans AE. Studies of T, B, and null lymphocytes during the course of acute lymphocytic leukemia. Cancer. 1977 Apr; 39(4):1489-94. PMID: 300648.
      Citations:    
    120. Hann HW, London WT, Sutnick AI, Blumberg BS, Lustbader E, Carim HM, Evans AE, Kay HE, MacLennan IC. Studies of parents of children with acute leukemia. J Natl Cancer Inst. 1975 Jun; 54(6):1299-305. PMID: 48551.
      Citations:    
    121. Jaffe N, Traggis D, Das L, Frauenberger G, Hann HW, Kim BS, Bishop Y. Favorable remission induction rate with twice weekly doses of L-asparaginase. Cancer Res. 1973 Jan; 33(1):1-4. PMID: 4565907.
      Citations:    
    122. Jaffe N, Traggis D, Das L, Moloney WC, Hann HW, Kim BS, Nair R. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res. 1971 Jul; 31(7):942-9. PMID: 4327086.
      Citations:    
    Hann's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (369)
    Explore
    _
    Co-Authors (28)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _